NASDAQ:KALV

Kalvista Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy KALV

*Your capital is at risk

$26.95

+0.0100 (+0.0371%)

At Close: Jun 03, 2026

KalVista Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -42.42. In total, the insiders bought 1.17M and sold 342.12K KALV shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-42.42
● Buy	1.17M shares
● Sell	342.12K shares
67% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence Mar 25, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -42.42. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 27, 2026 Buy	Common Stock M-Exempt	Yea Christopher Chief Development Officer	Officer	33 800 Value: $239.0K
May 27, 2026 Sell	Common Stock S-Sale	Yea Christopher Chief Development Officer	Officer	33 800 Value: $905.2K
May 27, 2026 Buy	Employee Stock Option (Right to Buy) M-Exempt	Yea Christopher Chief Development Officer	Officer	33 800 Value: $239.0K
May 26, 2026 Sell	Common Stock S-Sale	Yea Christopher Chief Development Officer	Officer	1 966 Value: $52.6K
May 26, 2026 Sell	Common Stock S-Sale	Sweeny Nicole Chief Commercial Officer	Officer	1 489 Value: $39.9K
May 26, 2026 Sell	Common Stock S-Sale	Audhya Paul K. Chief Medical Officer	Officer	2 239 Value: $60.0K
May 22, 2026 Buy	Restricted Stock Unit M-Exempt	Audhya Paul K. Chief Medical Officer	Officer	5 000 Value: $134.0K
May 22, 2026 Buy	Common Stock M-Exempt	Yea Christopher Chief Development Officer	Officer	3 125 Value: $83.7K
May 22, 2026 Buy	Restricted Stock Unit M-Exempt	Yea Christopher Chief Development Officer	Officer	3 125 Value: $83.7K
May 22, 2026 Buy	Common Stock M-Exempt	Sweeny Nicole Chief Commercial Officer	Officer	5 000 Value: $134.0K
May 22, 2026 Buy	Restricted Stock Unit M-Exempt	Sweeny Nicole Chief Commercial Officer	Officer	5 000 Value: $134.0K
May 22, 2026 Buy	Common Stock M-Exempt	Audhya Paul K. Chief Medical Officer	Officer	5 000 Value: $134.0K
May 22, 2026 Sell	Common Stock S-Sale	Yea Christopher Chief Development Officer	Officer	2 358 Value: $63.2K
May 22, 2026 Sell	Common Stock S-Sale	Audhya Paul K. Chief Medical Officer	Officer	2 685 Value: $71.9K
May 22, 2026 Sell	Common Stock S-Sale	Piekos Brian Chief Financial Officer	C-Suite Officer	1 489 Value: $39.9K
May 22, 2026 Sell	Common Stock S-Sale	Palleiko Benjamin L Chief Executive Officer	CEO / President	10 926 Value: $292.6K
May 22, 2026 Sell	Common Stock S-Sale	Sweeny Nicole Chief Commercial Officer	Officer	1 861 Value: $49.8K
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Yea Christopher Chief Development Officer	Officer	3 750 Value: $100.4K
May 21, 2026 Buy	Common Stock M-Exempt	Audhya Paul K. Chief Medical Officer	Officer	6 250 Value: $167.3K
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Audhya Paul K. Chief Medical Officer	Officer	6 250 Value: $167.3K
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Piekos Brian Chief Financial Officer	C-Suite Officer	5 000 Value: $133.9K
May 21, 2026 Buy	Common Stock M-Exempt	Piekos Brian Chief Financial Officer	C-Suite Officer	5 000 Value: $133.9K
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Palleiko Benjamin L Chief Executive Officer	CEO / President	23 250 Value: $622.4K
May 21, 2026 Buy	Common Stock M-Exempt	Sweeny Nicole Chief Commercial Officer	Officer	6 250 Value: $167.3K
May 21, 2026 Buy	Restricted Stock Unit M-Exempt	Sweeny Nicole Chief Commercial Officer	Officer	6 250 Value: $167.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KALVISTA PHARMACEUTICALS INC

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ...

Read Full Profile Here